Literature DB >> 32890013

Mirels Scores in Patients Undergoing Prophylactic Stabilization for Femoral Metastatic Bone Disease in the Veterans Administration Healthcare System.

Duncan C Ramsey1, Phillip W Lam, James Hayden, Yee-Cheen Doung, Kenneth R Gundle.   

Abstract

INTRODUCTION: A retrospective review was performed for patients in the Veterans Administration Healthcare System who underwent prophylactic stabilization of the femur for metastatic disease. The goal was to evaluate indications for prophylactic stabilization through Mirels criteria.
METHODS: All veterans who underwent inpatient prophylactic femoral stabilization between October 2010 and September 2015 were identified. Procedure and demographic variables were collected by using chart review. Provider notes and radiographs were reviewed to calculate Mirels scores.
RESULTS: Ninety-two patients underwent confirmed prophylactic stabilization for metastatic bone disease. Lung cancer and multiple myeloma accounted for most lesions. The mean Mirels score was 10.3 (range 7 to 12). 3.2% of patients had a score of 7, and 6.5% had a score of 8. Most lesions were peritrochanteric (66%) and lytic (85%). There was more variability in size (mean 2.3), with 15% being under one third of bony width and 38% between one and two-thirds. The mean pain score was 2.5; 73% reported functional pain. Of lytic and peritrochanteric lesions (53% of all cases), 55% were less than two-thirds the cortical width and 31% lacked functional pain.
CONCLUSION: This retrospective study of prophylactically stabilized metastatic lesions revealed that more than 90% of patients had Mirels scores greater than 8, suggesting a substantial risk of pathologic fracture. Over half of all stabilized lesions were peritrochanteric and lytic. These criteria alone achieve a minimum Mirels score of 8; however, one-third of these lacked functional pain. Notably, Mirels' original paper found location and type criteria to be the least predictive of impending fracture. Contrariwise, functional pain was the most accurate predictor. Multiple studies have found poor specificity of the Mirels criteria. The high scores achievable by the location and type criteria may represent an overrepresentation of their contribution to fracture risk. Reconsideration of the relative weights of each criterion warrants further examination.

Entities:  

Mesh:

Year:  2020        PMID: 32890013      PMCID: PMC7469986          DOI: 10.5435/JAAOSGlobal-D-20-00141

Source DB:  PubMed          Journal:  J Am Acad Orthop Surg Glob Res Rev        ISSN: 2474-7661


In the United States, metastatic bone disease affects between 280,000 and 330,000 people, contributing significantly to morbidity and healthcare cost in the United States.[1-3] Metastatic lesions put patients at risk for pathological fracture, leading to substantial morbidity associated with hospital admission, pain, worsening quality of life, and perhaps decreased overall survival.[4] The femur is the most common site of metastatic disease and pathologic fracture in the appendicular skeleton.[5] Several authors have proposed predictive models for identifying metastatic lesions that represent impending pathological fractures.[67891011] The scoring system created by Mirels[11] is the most widely used system today. This system incorporates lesion size, location, type, and pain characteristics. Each of these four subcategories are evaluated on a 1 to 3 scale and summed. Total scores above an eight are considered at high risk of fracture, therefore warranting stabilization. A score of exactly 8 is considered borderline, and clinical judgment is used to make a final treatment decision. Mirels' criteria have been shown to be valid, reliable, and reproducible in subsequent studies for both upper and lower extremity lesions.[12-14] When a hard score cutoff of ≥9 is used, it has been shown to be highly sensitive (>91%) but significantly less specific (35%) for predicting fracture. Some authors recommend using the system as a guide with heavier weight given to mechanical pain.[15] Currently, there is little known about actual practice patterns and indications used for prophylactic stabilization of metastatic lesions. To this end, a retrospective review was performed for patients in the nationwide Veterans Administration Healthcare System who underwent prophylactic stabilization of the femur for metastatic disease. The goal was to evaluate indications for prophylactic stabilization through Mirels criteria.

Methods

This retrospective study was approved by the institutional review board. All veterans who underwent inpatient prophylactic femoral stabilization between October 2010 and September 2015 were identified using common procedural terminology codes 27495 or 27181 through the Veterans Affairs Informatics and Computing Infrastructure Corporate Data Warehouse database. Those receiving care outside VA hospitals but paid for by the VA were excluded. Procedure date and location and demographic variables were collected from Veterans Affairs Informatics and Computing Infrastructure Corporate Data Warehouse using Structured Query Language. All electronic medical records identified were manually reviewed to establish the accuracy of common procedural terminology codes. Ninety-two eligible patients were found to have undergone prophylactic stabilization for femoral metastasis. Provider notes and biopsy results were reviewed to identify histological diagnosis and the pain subscores for the Mirels criteria. Multidirectional preoperative radiographs were reviewed by the authors to determine location, size, and type subscores. Descriptive statistics were performed. Statistical analysis was performed using R version 2.4.3.[16] This study was designed and reported using the guidelines of Strengthening the Reporting of Observational Studies in Epidemiology.[17]

Results

Ninety-two patients were identified who underwent confirmed prophylactic stabilization for metastatic bone disease. Histopathological diagnoses are shown in Table 1. Lung cancer (32%) and multiple myeloma (20%) account for most cases. The mean Mirels score was 10.3 (median 11, 95% confidence interval 10.1 to 10.6; Table 2). Only 3.2% of patients had a score of 7, and 6.5% had a score of 8. Most lesions (66%) were peritrochanteric, and lytic lesions dominated the sample (85%). There was more variability in size (mean 2.3, median 2), with 15% being under one third of bony width, 38% between one and two-thirds, and 47% being greater than two thirds the width. The pain score had a mean of 2.5 (median 3), with 73% reporting functional pain (Table 3).
Table 1

Cancer Diagnoses Among Veterans Treated With Prophylactic Femoral Nailing

Diagnosis%
Lung32
Multiple myeloma20
Prostate9
Renal7
Hepatocellular carcinoma4
Head and neck3
Lymphoma3
Unknown3
Bladder2
Other9
Table 2

Distribution of Mirels Scores

ScoreFrequency
73
86
916
1018
1131
1218

Mean score is 10.3 with a median score of 11.

Table 3

Distribution of Scores for Individual Mirels Subcategories

CriteriaMean (Median)Score
123
Location2.7 (3)03161
Pain2.6 (3)151067
Size2.3 (2)143543
Type2.8 (3)6878
Cancer Diagnoses Among Veterans Treated With Prophylactic Femoral Nailing Distribution of Mirels Scores Mean score is 10.3 with a median score of 11. Distribution of Scores for Individual Mirels Subcategories Fifty-three percent of patients had lytic and peritrochanteric lesions. Of these, approximately half (55%) were less than two-thirds the cortical width and 31% lacked functional pain.

Conclusions and Discussion

This national retrospective study of prophylactically stabilized metastatic lesions revealed that more than 90% of patients had Mirels scores greater than 8, suggesting a substantial risk of pathologic fracture. Patients who sustain a pathological fracture have worse quality of life and are at higher risk for depression and anxiety, and Saad et al. reported that pathological fracture is associated with a 20% to 32% increased risk of death compared with patients with metastatic lesions that did not fracture.[18,19] Prophylactically stabilizing a metastatic lesion (compared with the fixation of a completed pathological fracture) is cost-effective, lessens the burden on the healthcare system, and is associated with an improvement in overall survival.[4,20,21] Furthermore, these surgeries tend to be less morbid with shorter hospital stays and higher likelihood of discharge to home rather than a facility. Location and lesion type showed very little variation; stabilized lesions were overwhelmingly lytic and located in the peritrochanteric region (Figure 1). There were no patients with a location score of 1 (by design, as we only evaluated femur stabilization), and only 6 (7%) with a type score of 1. Hence, over half of all patients achieved a Mirels score of at least 8 by the location and type criteria alone. Notably, however, the original paper by Mirels found that location and lesion type were by far the least accurate predictors of the four criteria.
Figure 1

Diagram showing the distribution of Mirels subscores among patients who underwent femoral prophylactic stabilization.

Diagram showing the distribution of Mirels subscores among patients who underwent femoral prophylactic stabilization. One third of the current patients lacked functional (i.e., weight-bearing) pain. As Mirels' original study noted functional pain to be the most accurate predictor of impending fracture, the high scores achievable by the more poorly predictive location and type criteria alone combined with the low prevalence of functional pain may imply an overrepresentation of the lesion size and character criteria. This likely represents the driving force behind the very poor specificity of the Mirels criteria demonstrated in previous studies, including a rather poor 33% in Mirels' original paper.[11,14] Reconsideration of the relative weights of each of the subcriteria warrants further study. Alternative predictive rubrics exist but are much less often employed and lack the abundant validation studies of the Mirels system. Snell and Beals[22] reported moderate success in predicting pathological femur fractures in patients with breast cancer based on the lesion's size, cortical involvement, and pain. Fidler,[10] in 1981, endorsed basing the decision to prophylactically stabilize on the amount of cortex affected as judged using orthogonal radiographs. They set a threshold of 50% to 75% of cortex involvement for consideration of stabilization. Harrington[6] suggested that indications for prophylactic stabilization include lesions larger than 2.5 cm or comprising more than half the bone's diameter, lytic lesions, or refractory pain. CT-based structural rigidity analysis and finite element analysis have also been studied, with improved predictive accuracy, sensitivity, and specificity when compared with the Mirels criteria.[8,23,24] This study was limited to patients that that underwent surgery; additionally, women as well as patients with breast cancer are underrepresented in the VA healthcare system. Strengths include the number of patients, external generalizability across a national healthcare system, and the direct review of radiographs and chart notes. We did not include patients whose metastatic lesions were treated prophylactically with an arthroplasty, and there remains controversy on when intramedullary nailing versus arthroplasty is indicated.[25] We did not investigate the timing of radiation, use of narcotics, or any interaction with chemotherapy. In addition, for understanding the indications for prophylactic stabilization, we would ideally identify all femurs at risk for fracture. While complex from an informatics perspective, the VA data may provide an avenue to further our understanding of these important topics in subsequent investigations. Verification and comparison with other healthcare delivery systems may be warranted. Demonstrating the indications for prophylactic nailing as currently practiced is important to future research on interventions aimed to minimize both the risk of pathologic fracture and unnecessary surgery.
  24 in total

Review 1.  Surgical management of metastatic long bone fractures: principles and techniques.

Authors:  John Alan Scolaro; Richard D Lackman
Journal:  J Am Acad Orthop Surg       Date:  2014-02       Impact factor: 3.020

2.  CT-based Structural Rigidity Analysis Is More Accurate Than Mirels Scoring for Fracture Prediction in Metastatic Femoral Lesions.

Authors:  Timothy A Damron; Ara Nazarian; Vahid Entezari; Carlos Brown; William Grant; Nathan Calderon; David Zurakowski; Richard M Terek; Megan E Anderson; Edward Y Cheng; Albert J Aboulafia; Mark C Gebhardt; Brian D Snyder
Journal:  Clin Orthop Relat Res       Date:  2016-03       Impact factor: 4.176

Review 3.  Bone metastases: pathophysiology and management policy.

Authors:  O S Nielsen; A J Munro; I F Tannock
Journal:  J Clin Oncol       Date:  1991-03       Impact factor: 44.544

4.  Simple radiographic parameter predicts fracturing in metastatic femoral bone lesions: results from a randomised trial.

Authors:  Yvette M van der Linden; Herman M Kroon; Sander P D S Dijkstra; Judith J Lok; Ed M Noordijk; Jan Willem H Leer; Corrie A M Marijnen
Journal:  Radiother Oncol       Date:  2003-10       Impact factor: 6.280

5.  What Factors are Associated With Quality Of Life, Pain Interference, Anxiety, and Depression in Patients With Metastatic Bone Disease?

Authors:  Q M J van der Vliet; N R Paulino Pereira; S J Janssen; F J Hornicek; M L Ferrone; J A M Bramer; C N van Dijk; J H Schwab
Journal:  Clin Orthop Relat Res       Date:  2016-10-17       Impact factor: 4.176

6.  Critical evaluation of Mirels' rating system for impending pathologic fractures.

Authors:  Timothy A Damron; Hannah Morgan; Dave Prakash; William Grant; Jesse Aronowitz; John Heiner
Journal:  Clin Orthop Relat Res       Date:  2003-10       Impact factor: 4.176

7.  Is Prophylactic Intervention More Cost-effective Than the Treatment of Pathologic Fractures in Metastatic Bone Disease?

Authors:  Alan T Blank; Daniel M Lerman; Neeraj M Patel; Timothy B Rapp
Journal:  Clin Orthop Relat Res       Date:  2016-03-28       Impact factor: 4.176

8.  Pathological fracture risk assessment in patients with femoral metastases using CT-based finite element methods. A retrospective clinical study.

Authors:  Amir Sternheim; Ornit Giladi; Yair Gortzak; Michael Drexler; Moshe Salai; Nir Trabelsi; Charles Milgrom; Zohar Yosibash
Journal:  Bone       Date:  2018-02-20       Impact factor: 4.398

Review 9.  The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies.

Authors:  Erik von Elm; Douglas G Altman; Matthias Egger; Stuart J Pocock; Peter C Gøtzsche; Jan P Vandenbroucke
Journal:  PLoS Med       Date:  2007-10-16       Impact factor: 11.069

10.  Prevalence of bone metastases and bone-targeting agent use among solid tumor patients in the United States.

Authors:  Rohini K Hernandez; Avanti Adhia; Sally W Wade; Emily O'Connor; Jorge Arellano; Kevin Francis; Hasmik Alvrtsyan; Ryan P Million; Alexander Liede
Journal:  Clin Epidemiol       Date:  2015-07-17       Impact factor: 4.790

View more
  2 in total

1.  Predicting Fracture Risk in Patients with Metastatic Bone Disease of the Femur: A Pictorial Review Using Three Different Techniques.

Authors:  Shannon M Kaupp; Kenneth A Mann; Mark A Miller; Timothy A Damron
Journal:  Adv Orthop       Date:  2021-06-16

Review 2.  Safety, Precautions, and Modalities in Cancer Rehabilitation: an Updated Review.

Authors:  Jasmine Y Zheng; Alyssa C Mixon; Mitra D McLarney
Journal:  Curr Phys Med Rehabil Rep       Date:  2021-06-19
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.